Temporal Lobe Epilepsy Mechanisms and Therapeutic Approaches

Temporal lobe epilepsy (TLE) represents the most prevalent focal epilepsy in adults, characterised by recurrent seizures arising from medial temporal structures, especially the hippocampus. Pathogenic mechanisms include an imbalance between excitatory glutamatergic and inhibitory GABAergic transmission, hippocampal sclerosis with neuronal loss and reactive gliosis, synaptic reorganisation and neuroinflammatory cascades that perpetuate network hyperexcitability. Ionic channel dysfunction and excessive intracellular calcium play central roles in excitotoxic injury, while alterations in blood–brain barrier integrity and metabolic pathways further promote epileptogenesis. Current management relies on antiseizure medications targeting ion channels and neurotransmitter receptors, dietary therapies such as ketogenic diets and surgical resection in pharmacoresistant cases. Emerging strategies seek to modulate neuroinflammation, enhance neuromodulation through electrical or molecular interventions, identify fluid biomarkers for early diagnosis and apply gene or cell therapies to restore network homeostasis. Together, these insights pave the way for personalised approaches that address both seizure control and the underlying disease mechanisms.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Temporal Lobe Epilepsy Mechanisms and Therapeutic Approaches publication trend

The graph below shows the total number of articles in temporal lobe epilepsy mechanisms and therapeutic approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Hippocampal sclerosis: Loss of neurons and reactive glial proliferation within the hippocampus, commonly observed in TLE.

Excitatory/inhibitory balance: Equilibrium between excitatory glutamate and inhibitory GABA neurotransmission that maintains neural network stability.

Neuroinflammation: Activation of glial cells and release of cytokines within the central nervous system contributing to neuronal dysfunction.

Neuromodulation: Targeted electrical or pharmacological intervention designed to alter neural circuit activity.

Biomarker: A measurable biological indicator used for diagnosis, prognosis or monitoring of a disease state.

Blood–brain barrier: A selective physiological barrier controlling the passage of substances between the bloodstream and brain tissue.

References

1. A phosphodiesterase 4 (PDE4) inhibitor, amlexanox, reduces neuroinflammation and neuronal death after pilocarpine-induced seizure. Neurotherapeutics (2024).
2. Comparative analysis of hippocampal extracellular space uncovers widely altered peptidome upon epileptic seizure in urethane-anaesthetized rats. Fluids and Barriers of the CNS (2024).
3. Susceptibility to Pentylenetetrazole-Induced Seizures in Mice with Distinct Activity of the Endogenous Opioid System. International Journal of Molecular Sciences (2024).